Abstract: Disclosed herein are methods, devices, and systems for monitoring fluid outflow behavior of an eye of a subject, for example, during ocular surgery. Changes to intraocular pressure can reflect fluid outflow behavior. Fluid outflow behavior can be a critical factor in the successful outcome of a surgery and determining likelihood of post-operative side effects. Large fluctuations in intraocular pressure, ocular hypertension, and hypotony can be associated with vision loss or poor ocular health.

Abstract: Introduced here approaches to developing, training, and implementing algorithms to cardiac dysfunction through automated analysis of physiological data. As an example, a model may be developed and then trained to quantify left and right ventricular dysfunction using electrocardiogram waveform data that is associated with a population of individuals who are diverse in terms of age, gender, ethnicity, socioeconomic status, and the like. This approach to training allows the model to predict the presence of left and right ventricular dysfunction in a diverse population. Also introduced here is a regression framework for predicting numeric values of left ventricular ejection fraction.

Abstract: Described herein are chimeric Newcastle disease viruses comprising a packaged genome comprising a transgene encoding interleukin-12. The chimeric Newcastle disease viruses and compositions thereof are useful in combination with an antagonist of programmed cell death protein 1 (“PD-1”) or a ligand thereof in the treatment of cancer. In particular, described herein are methods for treating cancer comprising administering the chimeric Newcastle disease viruses in combination with an antagonist of PD-1 or a ligand thereof, wherein the chimeric Newcastle disease virus comprises a packaged genome comprising a transgene encoding interleukin-12.

Abstract: Provided herein are chimeric hemagglutinin (HA) polypeptides and uses thereof for inducing an immune response (e.g., an antibody response) against influenza virus. Also provided herein are methods of generating antibodies to the chimeric HA polypeptides in a subject.

Abstract: Methods for designing bivalent compounds which selectively degrade/disrupt EZH2 and compositions and methods of using such degraders/disruptors to treat EZH2-mediated cancer are provided.

Abstract: The present disclosure is concerned with small molecule modulators of KLF15 signaling useful for treating various disorders such as, for example, kidney disease (e.g., chronic kidney disease), heart disease, obesity, or a neurodegenerative disorder (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present invention relates to methods of treatment or prevention of fatty liver disease, nonalcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH), cirrhosis, liver fibrosis, hepatocellular carcinoma and related liver disease and conditions by administering an effective amount of a GABAB agonist, lesogaberan (AZD3355), or related compounds.

Abstract: Provided are compositions and methods for treating or reducing the likelihood of the development of epilepsy in an individual. The method includes administering to the central nervous system of an individual in need of such treatment a therapeutically effective amount of an agent capable of increasing the expression and/or activity of miR-128.

Abstract: Systems and methods to label structures of interest in tissue slide images are described.

Abstract: A method for treating a medical condition in a patient in need thereof is provided. The method includes applying light to the patient thereby stimulating the immune system of the patient, wherein the applying includes irradiating substantially the entire body of the patient with high intensity blue light having a wavelength, intensity, and duration configured to provide immune system stimulation sufficient to treat the medical condition, the stimulation including increasing the population of T-cells in the patient's bloodstream to treat the medical condition. Also included is a method for activating T cells in a subject in need thereof.

Abstract: Provided herein are chimeric hemagglutinin (HA) polypeptides and uses thereof for inducing an immune response (e.g., an antibody response) against influenza virus. Also provided herein are methods of generating antibodies to the chimeric HA polypeptides in a subject.

Abstract: A genus of dihydropyridine chemical modulators of synaptojanin is disclosed. These modulators are selective inhibitors of synaptojanin 1 and may be used to treat cognitive impairment or traumatic brain injury, including promoting regeneration in cases of traumatic brain injury, or for treating neurodegenerative disorders.

Abstract: A system and method for determining native cardiac output of a heart while maintaining operation of an intracardiac blood pump includes determining a current drawn by the pump motor, a blood pressure within the ascending aorta, and a change in the blood temperature based on a thermodilution technique. An intracardiac blood pump positioned in the aorta includes at least one sensor for determining a motor current and blood pressure and a thermistor for determining the change in blood temperature after a precise fluid bolus has been introduced into the vasculature. A processor receives current, pressure, and temperature measurements, and calculates a pump flow output and a total cardiac output from which the native cardiac output is calculated. The native cardiac output and other clinically relevant variables derived from the measurements inform decisions related to continued therapeutic care, including increasing or decreasing cardiac assistance provided by the intracardiac pump.

Abstract: Disclosed is an expression regulatory system for cell-specific transcription (expression) of a protein of interest, for example a cell cycle inducer that reactivates proliferation in adult or neonatal cardiomyocytes or insulin-producing beta cells. The expression regulatory system comprises a first nucleic acid that encodes a microRNA recognition element that specifically binds a target cell miR, and a translation suppressor protein; and a second nucleic acid that comprises a suppressor protein interaction motif that binds the translation suppressor protein, and a gene that encodes a protein of interest. When a cell of interest is co-transfected with the first and second nucleic acids of the system, the protein of interest expressed in a cell-specific fashion.

Abstract: Disclosed herein are methods and compositions for preventing pain induction, interrupting pain signaling stemming from various insults, or alleviating pain perception in a subject.

Abstract: A method of decreasing degeneration of retinal ganglion cells in a subject is provided, including administering to the subject a composition to increase activity of a calcium-calmodulin dependent kinase (CaMK) or cyclic-AMP response element-binding protein (CREB), wherein the composition comprises the CaMK or CREB or a polynucleotide encoding the CaMK or the CREB. Also provided is a method for treating vision loss in a subject is provided, including administering to the subject a composition to increase activity of a CaMK or CREB, wherein the composition comprises the CaMK or CREB or a polynucleotide encoding the CaMK or the CREB. Also provided is a pharmaceutical composition, including a polynucleotide and a vector, wherein the polynucleotide includes a retinal ganglion cell promoter and encodes a CaMK or CREB.

Abstract: Provided herein are antibodies that bind to neuraminidase (NA) of different strains of influenza B virus, host cells for producing such antibodies, and kits comprising such antibodies. Also provided herein are compositions comprising antibodies that bind to NA of different strains of influenza B virus and methods of using such antibodies to diagnose, prevent or treat influenza virus disease.

Abstract: A kit is provided for delivering local radiation to a tumor while also causing tumor devascularization. The kit includes a first liquid radioembolic agent for treatment of at least a first region of the tumor and a second liquid radioembolic agent for treatment of at least a second region of the tumor. The first liquid radioembolic agent includes: a biocompatible polymer or prepolymer and a first radioisotope having a first type of ionizing radiation for treatment of the first region of the tumor. The second liquid radioembolic agent includes: a biocompatible polymer or prepolymer and a second radioisotope having a second type of ionizing radiation for treatment of the second region of the tumor. The second type of ionizing radiation is different than the first type of ionizing radiation.

Abstract: Systems and methods for determining whether a subject has a cardiovascular abnormality are provided. An electrocardiogram of the subject is obtained, the electrocardiogram representing a plurality of time intervals summing to a total time interval and comprising, for each lead in a plurality of leads, a plurality of data points representing electronic measurements at the respective lead at a different time interval in the plurality of time intervals. For each lead, a plurality of sub-waveforms is obtained from the electrocardiogram, each sub-waveform (i) having a common duration that is less than the total time interval and that represents a fixed multiple of a reference heartbeat duration, and (ii) offset from a beginning of the electrocardiogram by a unique multiple of a sliding parameter. The plurality of sub-waveforms for each lead is inputted into a neural network comprising a plurality of parameters, obtaining an indication of cardiovascular abnormality.

Abstract: The invention relates generally to the THAP1 gene and mutations in this gene, as well as the THAP1 protein and mutations in this protein, that are associated with dystonia. The invention relates to the identification, isolation, cloning and characterization of the DNA sequence corresponding to the wild type and mutant THAP1 genes, as well as isolation and characterization of their transcripts and gene products. The invention further relates to methods and kits useful for detecting mutations in THAP1 that are associated with dystonia, as well as to methods and kits useful for diagnosing dystonia. The present invention also relates to therapies for treating dystonia, including gene therapeutics and protein/antibody based therapeutics.